Sign in:
Email
 Password  save:
  
 Company Reports 
 
   
My Recent Searches
  Help
 
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$88.61 0.87 (0.99%) as of 4:30 Wed 3/27


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 16.69(B)
Last Volume: 1,031,697 Avg Vol: 1,398,626
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:

    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:

     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.


 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 92,341 116,105 269,465 610,463
Total Sell Value $8,237,699 $10,489,308 $24,880,826 $57,517,351
Total People Sold 3 4 5 8
Total Sell Transactions 9 11 22 59
End Date 2023-12-28 2023-09-26 2023-03-28 2022-03-28

   
Records found: 1213
  Page 4 of 49  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

 
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-07-15 4 OE $63.70 $63,698 I/I 1,000 48,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-07-15 4 OE $12.99 $12,990 I/I 1,000 49,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-07-01 4 AS $59.56 $243,063 D/D (4,066) 37,950     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-07-01 4 AS $60.00 $600,000 D/D (10,000) 43,266     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-07-01 4 OE $11.05 $110,500 D/D 10,000 53,266     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-06-19 4 A $58.57 $1,057 D/D 18 68,717     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-12 4 OE $12.99 $64,950 I/I 5,000 48,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-05 4 OE $58.68 $593,406 I/I 10,000 43,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-05 4 OE $12.99 $129,900 I/I 10,000 53,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-04 4 OE $60.72 $607,194 I/I 10,000 43,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-06-04 4 OE $12.99 $129,900 I/I 10,000 53,740     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-06-03 4 AS $58.32 $64,036 D/D (1,098) 43,266     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-06-03 4 AS $58.34 $28,763 D/D (493) 14,880     -
   Mueller Brian VP, Corporate Controller   •       –      –    2013-05-31 4 D $62.70 $25,895 D/D (413) 8,447     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-05-31 4 D $62.70 $18,622 D/D (297) 15,373     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-31 4 OE $12.99 $38,970 I/I 3,000 43,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-05-29 4 D $64.46 $269,701 D/D (4,184) 42,016     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-05-23 4 AS $67.16 $584,981 D/D (8,710) 44,364     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-23 4 GA $0.00 $0 I/I 10,131 40,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-23 4 GD $0.00 $0 D/D 10,131 115,770     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-05-22 4 AS $65.66 $781,240 D/D (11,899) 53,074     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2013-05-22 4 OE $11.05 $110,500 D/D 10,000 64,973     -
   Wood Mark VP, Human Resources   •       –      –    2013-05-22 4 AS $67.12 $208,283 D/D (3,103) 20,277     -
   Wood Mark VP, Human Resources   •       –      –    2013-05-22 4 OE $14.39 $72,405 D/D 3,103 23,380     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-05-21 4 AS $64.14 $128,279 I/I (2,000) 30,609     -

  1213 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 4 of 49
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed